药品“二次议价”该管不该禁

发布时间：2018-06-16 12:11

本文选题：二次议价 + 药价虚高　；参考：《卫生经济研究》2016年02期

【摘要】：当前,治理药价虚高的各项举措——政府控制、招标采购、医保议价,都收效甚微;"二次议价"脱颖而出,却受到了诸多责难,一是把不属于"二次议价"应该承载的职能强加到"二次议价"头上,二是把可能导致的问题断言成必然会出现的问题。对此,加强对药品"二次议价"的管理才是正确的选择,而非"一禁了之"。
[Abstract]:At present, the various measures to deal with the false high drug prices-government control, bidding and procurement, and medical insurance bargaining-have had little effect. "second bargaining" has come to the fore, but it has been criticized by many people. One is to impose the functions which should not belong to "second bargaining" on the head of "second bargaining", the other is to assert the possible problems as inevitable problems. Therefore, it is the right choice to strengthen the management of the second negotiation of drugs, not to ban it.
【作者单位】：安徽省农村卫生协会;
【分类号】：R95

【相似文献】